Budget impact of lecanemab for medicare beneficiaries with early Alzheimer's disease in the United States: a subgroup analysis.

IF 1.5 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-05-22 DOI:10.1080/14737167.2025.2507427

Vassiki Sanogo, Reem Dhayan Saud Almutairi, Vakaramoko Diaby

{"title":"Budget impact of lecanemab for medicare beneficiaries with early Alzheimer's disease in the United States: a subgroup analysis.","authors":"Vassiki Sanogo, Reem Dhayan Saud Almutairi, Vakaramoko Diaby","doi":"10.1080/14737167.2025.2507427","DOIUrl":null,"url":null,"abstract":"Background: In 2024, Alzheimer's disease affected approximately 6.9 million Americans aged 65 and older. Current therapies include acetylcholinesterase inhibitors, N-methyl-D-aspartate receptor inhibitors, and monoclonal antibodies. With an economic burden surpassing $345 billion, $222 billion borne by Medicare and Medicaid, this study evaluates lecanemab's budgetary impact for early AD, including subgroup analyses by gender and race.Methods: A budget impact model evaluated LECA for early Alzheimer's disease, comparing scenarios with and without the therapy. Inputs included market share, costs, duration, and compliance. Gender and race subgroup analyses, annual costs, PMPM, PTMPM, and sensitivity analysis outcomes were assessed to explore parameter-driven variability comprehensively.Results: Introducing LECA for over 3.5 million eligible early AD patients in the U.S. may generate a three-year budget impact of $4.1 billion for Medicare. Incremental PMPM savings were $1.4, and PTMPM savings reached $24.1. Subgroup analyses revealed no significant gender or racial differences in PMPM and PTMPM, with variability only in overall budget impact. Sensitivity analyses indicate that enhanced healthcare resource utilization, reduced disease severity, and improved cost-efficiency among males contribute to strengthening Medicare's budget sustainability.Conclusions: Utilizing LECA as a treatment for early AD is expected to be cost saving with respect to Medicare budgets in the U.S.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-6"},"PeriodicalIF":1.5000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2025.2507427","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In 2024, Alzheimer's disease affected approximately 6.9 million Americans aged 65 and older. Current therapies include acetylcholinesterase inhibitors, N-methyl-D-aspartate receptor inhibitors, and monoclonal antibodies. With an economic burden surpassing $345 billion, $222 billion borne by Medicare and Medicaid, this study evaluates lecanemab's budgetary impact for early AD, including subgroup analyses by gender and race.

Methods: A budget impact model evaluated LECA for early Alzheimer's disease, comparing scenarios with and without the therapy. Inputs included market share, costs, duration, and compliance. Gender and race subgroup analyses, annual costs, PMPM, PTMPM, and sensitivity analysis outcomes were assessed to explore parameter-driven variability comprehensively.

Results: Introducing LECA for over 3.5 million eligible early AD patients in the U.S. may generate a three-year budget impact of $4.1 billion for Medicare. Incremental PMPM savings were $1.4, and PTMPM savings reached $24.1. Subgroup analyses revealed no significant gender or racial differences in PMPM and PTMPM, with variability only in overall budget impact. Sensitivity analyses indicate that enhanced healthcare resource utilization, reduced disease severity, and improved cost-efficiency among males contribute to strengthening Medicare's budget sustainability.

Conclusions: Utilizing LECA as a treatment for early AD is expected to be cost saving with respect to Medicare budgets in the U.S.

查看原文本刊更多论文

在美国，lecanemab对早期阿尔茨海默病医疗保险受益人的预算影响：一个亚组分析。

背景：2024年，阿尔茨海默病影响了大约690万65岁及以上的美国人。目前的治疗方法包括乙酰胆碱酯酶抑制剂、n -甲基- d -天冬氨酸受体抑制剂和单克隆抗体。由于医疗保险和医疗补助的经济负担超过3450亿美元，2220亿美元，本研究评估了lecanemab对早期AD的预算影响，包括按性别和种族进行亚组分析。方法：预算影响模型评估早期阿尔茨海默病的LECA，比较治疗前后的情况。输入包括市场份额、成本、持续时间和遵从性。评估性别和种族亚组分析、年度成本、PMPM、PTMPM和敏感性分析结果，以全面探索参数驱动的变异性。结果：在美国为超过350万符合条件的早期AD患者引入LECA可能会为Medicare带来41亿美元的三年预算影响。增量PMPM节省1.4美元，PTMPM节省24.1美元。亚组分析显示，PMPM和PTMPM在性别或种族方面没有显著差异，只有在总体预算影响方面存在差异。敏感性分析表明，男性医疗资源利用率的提高、疾病严重程度的降低和成本效率的提高有助于加强医疗保险预算的可持续性。结论：利用LECA作为早期AD的治疗有望节省美国医疗保险预算的成本。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Pharmacoeconomics & Outcomes Research HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY

CiteScore

4.00

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.